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intrahepatic hemodynamic changes, postoperative functional and
regenerative disorders in veno-occlusive hepatic regions may be
associated with the altered expression of hepatic transporters,
as pointed out by Kobbe et al. We have evaluated expression levels
of hepatic uptake transporters for ICG (organic anion-transporting
polypeptide 8 [OATP8, SLCO1B3] and Na+/taurocholate co-trans-
porting polypeptide [NTCP, SLC10A1]) [3] by using immunohisto-
chemical staining and gene expression analysis, in order to
elucidate mechanistic background of ICG accumulation in hepato-
cellular carcinoma following preoperative intravenous adminis-
tration, which enables real-time identiﬁcation of cancerous
tissues during hepatectomy [4]. It would be valuable to assess
the expression levels of hepatic transporters in veno-occlusive
and non-veno-occlusive regions, if postoperative tissue samples
are available to adopt similar approach. Gadoxetic acid-enhanced
magnetic resonance imaging is a good alternative to evaluate
postoperative portal uptake and excretion function in veno-occlu-
sive and non-veno-occlusive hepatic regions, although it should
be noted that gadoxetic acid can be excreted not only into bile
through multidrug resistance-associated protein 2 (MRP2), but
also into blood sinusoids through MRP3 [5], while ICG is exclu-
sively excreted into the bile canaliculus through MRP2.
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Open aEstimating ribavirin plasma exposure: Genetics or therapeutic
drug monitoring?To the Editor:
Rau and colleagues described the impact of genetic polymor-
phisms in SLC28 genes, encoding concentrative nucleoside trans-
porter 2 (CNT2) and 3 (CNT3) and inosine triphosphatase (ITPA)
variants, on ribavirin (RBV) serum levels, hemoglobin drop, and
therapeutic response in patients with HCV infection [1]. In their
paper, they cited our observation that single nucleotide polymor-
phism (SNP) in the SLC28A2 encoding region (rs11854484) is an
independent predictor of sustained virological response (SVR)
[2,3]. Our hypothesis was that this effect could be explained by
the different ability of CNT2 forms to internalize RBV within cells,
and not by a direct effect on RBV plasma levels.
In the era of dual PEG-interferon (PegIFN)/RBV therapy, most
of the studies that investigated the role of RBV pharmacokinetics
(Pk) found a clear association between higher RBV exposure and a
higher chance of both SVR and anaemia, as expected on the basis
of the recognized proportionality between RBV daily dose and
these two outcomes [4]. Even in most recent studies, where
patients were stratiﬁed according to human genetic polymor-
phisms, RBV Pk retained its signiﬁcant role in predicting both
efﬁcacy and toxicity in PegIFN/RBV intakers [2,3,5–7]. While theJournal of Hepatology 20
ccess under CC BY-NC-ND license.need for RBV as part of new triple therapies has been proven in
development trials [8], it remains to be determined whether
RBV Pk has still any impact on treatment outcomes with highly
effective direct acting antivirals (DAAs). Then, the ability to early
predict, with genetics or therapeutic drug monitoring (TDM),
ribavirin plasma concentrations at steady state retains its clinical
importance.
Rau and colleagues described the association between CNT2
SNPs and RBV plasma concentrations. It should be noted that
these PK/PG analyses were conducted on 67 patients only, with-
out dose correction veriﬁcation, including patient with modiﬁed
dosage. In addition, they only reported a trend for statistical sig-
niﬁcance for the association of RBV concentration and SLC28
genotypes [1]. Our observations did not support this association
[2,3]: CNT2 SNPs were not associated with plasma RBV concen-
trations (after 4 weeks) while adjusting for the dose pro kilogram
and for dose reduction, and only using several SNPs (rs11854484,
rs2413775 and rs1060896) in ‘‘unfavorable’’ (for lower ribavirin
concentrations) combinations (on 186 HCV+ patients), it was pos-
sible to demonstrate a statistical signiﬁcance (p = 0.009) (Fig. 1).
On the contrary, week 4 RBV plasma exposure seems to be nicely13 vol. 59 j 631–640 633
5000
4000
3000
2000
1000
0
0 1 2 3
18 93 31 44
R
ib
av
iri
n 
pl
as
m
a 
co
nc
en
tra
tio
n
(4
 w
k)
, n
g/
m
l
p = 0.006
Number of unfavourable
genetic CNT2 combinations
n = 
Fig. 1. Lower plasma concentrations of ribavirin were related to the higher
number of ‘‘unfavorable’’ CNT2 SNPs (rs11854484 [TT], rs2413775 [AT/TT] and
rs1060896 [CC]). Only the difference between group ‘‘0’’ and ‘‘3’’ is statistically
signiﬁcant (p = 0.006).
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E-mail address: antonio.davolio@unito.itpredicted by week 2 concentrations, suggesting a possible early
use of TDM to adjust the drug exposure both to enhance efﬁcacy
and reduce toxicity (p <0.001) [9,10].
We therefore have no clear answer to the question as to
whether genetic SLC28 transporter polymorphisms predict
ribavirin plasma levels. If RBV plasma exposure maintains its
clinical impact in new anti-HCV treatment studies comparative
evaluations of pharmacogenetics vs. early pharmacokinetics are
warranted. It should also be highlighted that the cost of a single
early (2 weeks) determination of ribavirin plasma concentration
does not signiﬁcantly impact on the overall expenditure associ-
ated with the use of (triple) anti-HCV therapy and may well con-
tribute to a fruitful tailored management.
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manuscript.Reply to: ‘‘Estimating ribavirin plasma exposure: Genetics or
therapeutic drug monitoring?’’0reported in our study [1]. Since our study included patients with
a different RBV dosage, drug serum levels were adjusted to dos-
age. To address this issue in the study design, we analyzed only
RBV serum levels at weeks 4 and 8 before eventual dose modiﬁ-
cation. As an alternative approach to account for drug dose
adjustment in pharmacokinetic studies, D’Avolio et al. adjusted
RBV concentrations for the dose pro kilogram and for dose reduc-
tion in their HCV positive patients. Although their ﬁndings did
not exactly replicate the results of our study, the described
association between lower RBV plasma concentrations and a
combination of ‘‘unfavorable’’ CNT2 SNPs must be taken asTo the Editor:
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RBV bioavailability, which has been described in our study [1].
In their letter to the editor, D’Avolio et al. described an association
between lower RBV plasma concentrations and a combination of
‘‘unfavorable’’ CNT2 SNPs (rs11854484, rs2413775, rs1060896) in
186 HCV patients. Interestingly, an association between RBV
plasma concentrations and rs11854484 alone was not seen as13 vol. 59 j 631–640
